• Je něco špatně v tomto záznamu ?

Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity

A. Špolcová, B. Mikulášková, M. Holubová, V. Nagelová, Z. Pirnik, J. Zemenová, M. Haluzík, B. Železná, MC. Galas, L. Maletínská,

. 2015 ; 45 (3) : 823-35.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010606

Numerous epidemiological and experimental studies have demonstrated that patients who suffer from metabolic disorders, such as type 2 diabetes mellitus (T2DM) or obesity, have higher risks of cognitive dysfunction and of Alzheimer's disease (AD). Impaired insulin signaling in the brain could contribute to the formation of neurofibrillary tangles, which contain an abnormally hyperphosphorylated tau protein. This study aimed to determine whether potential tau hyperphosphorylation could be detected in an obesity-induced pre-diabetes state and whether anorexigenic agents could affect this state. We demonstrated that 6-month-old mice with monosodium glutamate (MSG) obesity, which represent a model of obesity-induced pre-diabetes, had increased tau phosphorylation at Ser396 and Thr231 in the hippocampus compared with the controls, as determined by western blots. Two weeks of subcutaneous treatment with a lipidized analog of prolactin-releasing peptide (palm-PrRP31) or with the T2DM drug liraglutide, which both had a central anorexigenic effect, resulted in increased phosphorylation of the insulin cascade kinases PDK1 (Ser241), Akt (Thr308), and GSK-3β (Ser9). Furthermore, these drugs attenuated phosphorylation at Ser396, Thr231, and Thr212 of tau and of the primary tau kinases in the hippocampi of 6-month-old MSG-obese mice. We identified tau hyperphosphorylation in the obesity-induced pre-diabetes state in MSG-obese mice and demonstrated the beneficial effects of palm-PrRP31 and liraglutide, both of known central anorexigenic effects, on hippocampal insulin signaling and on tau phosphorylation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010606
003      
CZ-PrNML
005      
20161010142148.0
007      
ta
008      
160408s2015 ne f 000 0|engg|
009      
AR
024    7_
$a 10.3233/JAD-143150 $2 doi
024    7_
$a 10.3233/JAD-143150 $2 doi
035    __
$a (PubMed)25624414
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Špolcová, Andrea $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic INSERM UMR837, Lille, France, Jean Pierre Aubert Research Centre, Faculté de Médecine-Pòle Recherche, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université Droit et Santé de Lille, CHU-Lille, Lille, France.
245    10
$a Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity / $c A. Špolcová, B. Mikulášková, M. Holubová, V. Nagelová, Z. Pirnik, J. Zemenová, M. Haluzík, B. Železná, MC. Galas, L. Maletínská,
520    9_
$a Numerous epidemiological and experimental studies have demonstrated that patients who suffer from metabolic disorders, such as type 2 diabetes mellitus (T2DM) or obesity, have higher risks of cognitive dysfunction and of Alzheimer's disease (AD). Impaired insulin signaling in the brain could contribute to the formation of neurofibrillary tangles, which contain an abnormally hyperphosphorylated tau protein. This study aimed to determine whether potential tau hyperphosphorylation could be detected in an obesity-induced pre-diabetes state and whether anorexigenic agents could affect this state. We demonstrated that 6-month-old mice with monosodium glutamate (MSG) obesity, which represent a model of obesity-induced pre-diabetes, had increased tau phosphorylation at Ser396 and Thr231 in the hippocampus compared with the controls, as determined by western blots. Two weeks of subcutaneous treatment with a lipidized analog of prolactin-releasing peptide (palm-PrRP31) or with the T2DM drug liraglutide, which both had a central anorexigenic effect, resulted in increased phosphorylation of the insulin cascade kinases PDK1 (Ser241), Akt (Thr308), and GSK-3β (Ser9). Furthermore, these drugs attenuated phosphorylation at Ser396, Thr231, and Thr212 of tau and of the primary tau kinases in the hippocampi of 6-month-old MSG-obese mice. We identified tau hyperphosphorylation in the obesity-induced pre-diabetes state in MSG-obese mice and demonstrated the beneficial effects of palm-PrRP31 and liraglutide, both of known central anorexigenic effects, on hippocampal insulin signaling and on tau phosphorylation.
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a zvířata $7 D000818
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a chuťové esence $x toxicita $7 D005421
650    _2
$a glukagonu podobný peptid 1 $x genetika $x farmakologie $7 D052216
650    _2
$a glukózový toleranční test $7 D005951
650    _2
$a hipokampus $x účinky léků $x metabolismus $7 D006624
650    _2
$a inzuliny $x metabolismus $7 D061385
650    _2
$a lipopeptidy $x metabolismus $x terapeutické užití $7 D055666
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    12
$a obezita $x chemicky indukované $x farmakoterapie $x patologie $7 D009765
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a hormon uvolňující prolaktin $x účinky léků $x farmakologie $7 D056690
650    _2
$a receptory spřažené s G-proteiny $x metabolismus $7 D043562
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a glutamát sodný $x toxicita $7 D012970
650    _2
$a časové faktory $7 D013997
650    _2
$a proteiny tau $x metabolismus $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mikulášková, Barbora $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Holubová, Martina $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Nagelová, Veronika $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Pirnik, Zdenko $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic Laboratory of Functional Neuromorphology, Institute of Experimental Endocrinology, SAS, Bratislava, Slovak Republic Department of Human and Clinical Pharmacology, University of Veterinary Medicine, Košice, Slovak Republic.
700    1_
$a Zemenová, Jana $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic Institute of Chemical Technology, Department of Analytical Chemistry, Prague, Czech Republic.
700    1_
$a Haluzík, Martin $u Third Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic. $7 xx0206931
700    1_
$a Galas, Marie-Christine $u INSERM UMR837, Lille, France, Jean Pierre Aubert Research Centre, Faculté de Médecine-Pòle Recherche, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université Droit et Santé de Lille, CHU-Lille, Lille, France.
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
773    0_
$w MED00006350 $t Journal of Alzheimer's disease JAD $x 1875-8908 $g Roč. 45, č. 3 (2015), s. 823-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25624414 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20161010142542 $b ABA008
999    __
$a ok $b bmc $g 1114035 $s 934974
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 45 $c 3 $d 823-35 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace